CA2739705A1 - Efficient expression of truncated human rnaset2 in e. coli - Google Patents

Efficient expression of truncated human rnaset2 in e. coli Download PDF

Info

Publication number
CA2739705A1
CA2739705A1 CA2739705A CA2739705A CA2739705A1 CA 2739705 A1 CA2739705 A1 CA 2739705A1 CA 2739705 A CA2739705 A CA 2739705A CA 2739705 A CA2739705 A CA 2739705A CA 2739705 A1 CA2739705 A1 CA 2739705A1
Authority
CA
Canada
Prior art keywords
rnaset2
truncated
human
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2739705A
Other languages
English (en)
French (fr)
Inventor
Oded Shoseyov
Betty Schwartz
Levava Roiz
Patricia Smirnoff
Liron Nuttman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of CA2739705A1 publication Critical patent/CA2739705A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2739705A 2008-10-30 2009-10-29 Efficient expression of truncated human rnaset2 in e. coli Abandoned CA2739705A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19313408P 2008-10-30 2008-10-30
US61/193,134 2008-10-30
PCT/IL2009/001012 WO2010049933A1 (en) 2008-10-30 2009-10-29 Efficient expression of truncated human rnaset2 in e. coli

Publications (1)

Publication Number Publication Date
CA2739705A1 true CA2739705A1 (en) 2010-05-06

Family

ID=41694413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2739705A Abandoned CA2739705A1 (en) 2008-10-30 2009-10-29 Efficient expression of truncated human rnaset2 in e. coli

Country Status (8)

Country Link
US (1) US20110207667A1 (enExample)
EP (1) EP2346993A1 (enExample)
JP (1) JP2012507278A (enExample)
AU (1) AU2009309277A1 (enExample)
CA (1) CA2739705A1 (enExample)
EA (1) EA201100610A1 (enExample)
WO (1) WO2010049933A1 (enExample)
ZA (1) ZA201102615B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150009953A (ko) * 2012-02-29 2015-01-27 에프. 호프만-라 로슈 아게 1→3 해독 프레임 이동의 감소 방법
US11685935B2 (en) * 2013-05-29 2023-06-27 Cellectis Compact scaffold of Cas9 in the type II CRISPR system
US20160340659A1 (en) 2014-01-30 2016-11-24 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
JP7082945B2 (ja) * 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021830A1 (en) * 1999-09-24 2001-03-29 Ambion, Inc. Nuclease inhibitor cocktail
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
BRPI0516302A (pt) * 2004-09-29 2008-09-02 Yissun Res Dev Company Of The rnase t2 humana recombinante e suas utilizações
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof

Also Published As

Publication number Publication date
AU2009309277A1 (en) 2010-05-06
AU2009309277A8 (en) 2011-05-12
EA201100610A1 (ru) 2011-10-31
EP2346993A1 (en) 2011-07-27
US20110207667A1 (en) 2011-08-25
WO2010049933A1 (en) 2010-05-06
ZA201102615B (en) 2012-03-28
JP2012507278A (ja) 2012-03-29

Similar Documents

Publication Publication Date Title
Mykkänen et al. Characterization of human palladin, a microfilament-associated protein
Campuzano et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes
US8617867B2 (en) Methods of and compositions for inhibiting the proliferation of mammalian cells
KR100506786B1 (ko) 섬유아세포 성장인자-19
KR101838670B1 (ko) 미락 단백질
EP3341396B1 (en) Improved cell-permeable (icp)-socs3 recombinant protein and uses thereof
Iwashita et al. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations
JPH06508031A (ja) ヘレグリンの構造、生産および用途
US20020106796A1 (en) PAX8-PPARgamma nucleic acid molecules and polypeptides and uses thereof
US20110207667A1 (en) Efficient expression of truncated human rnaset2 in e. coli
EP1805319B1 (en) Recombinant human t2 rnase and uses thereof
KR20030074702A (ko) 모듈식 트랜스펙션 시스템
CA2145769A1 (en) Trophic factor having ion channel-inducing activity in neuronal cells
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
EP1403365B1 (en) Polypeptide unstabilizing protein in cells under aerobic conditions and dna encoding the same
CA2489446A1 (en) Ribonuclease zymogen design
CN1798838B (zh) 一种蛋白酶的抑制剂蛋白及其用途
CN101891824B (zh) 一种血管靶向可溶性融合蛋白TrxHis-hDll1-RGD
KR100448427B1 (ko) 신생 세포 성장을 억제하기 위한 방법 및 조성물
US20160340659A1 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
WO2009113965A1 (en) Isthmin derivatives for use in treating angiogenesis
CN101161676A (zh) 抑制hiv复制的突变型apobec3g分子及其应用
US20060134719A1 (en) Novel serine protease
CA2599566A1 (en) Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
EA049562B1 (ru) Гибридная белковая конструкция на основе рецептор-специфичного варианта trail с пептидом, специфичным к интегрину альфа v бета 3, для терапии солидных опухолей

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141022

FZDE Discontinued

Effective date: 20161031